Establishment Labs Holdings Inc. Q3 2026 Earnings Call Summary

Strategic Shift Toward Utilization and Category Expansion

Our analysts just identified a stock with the potential to be the next Nvidia. Tell us how you invest and we'll show you why it's our #1 pick. Tap here.

• Management is pivoting its U.S. strategy from account acquisition to increasing utilization within its 2,100 existing accounts, aiming to grow Motiva's current 43% average share of surgeon procedures.

• The minimally invasive platform, including Mia and Preserve, is serving as a primary entry point for new accounts, with nearly half of new European accounts starting with these technologies.

• Revenue growth of 33.9% was driven by significant U.S. market share gains and a 124% increase in minimally invasive revenue, which now represents approximately 15% of year-to-date sales.

• The company achieved its first quarter of positive free cash flow, which management attributes to increasing operating leverage and the scalability of the financial model as revenue grows.

• Innovation is being used as a tool for market expansion, with 88% of surveyed surgeons reporting that the Preserve procedure attracts patients who previously would not consider breast augmentation.

• A new long-term agreement with strategic supplier NuSil secures the silicone supply chain with volume-based pricing to support production scaling for future growth.

• Outside the U.S., direct markets grew 16% year-over-year, benefiting from optimized leadership and increased commercial focus in key European regions like Italy, the U.K., and Germany.

2027 Growth Drivers and Regulatory Milestones

• Management expects 25% revenue growth in 2027, supported by increased U.S. utilization, broader minimally invasive adoption, and the anticipated entry into the reconstruction market.

• The company is targeting sustained positive free cash flow for the full year 2027 through disciplined working capital management and continued revenue scaling.

• FDA approval for Motiva implants in reconstruction is expected by late 2026 or early 2027, with BIMO inspections already completed at clinical and sponsor sites.

• Gross margin expansion of 50 to 100 basis points is projected for 2027, though the final outcome will depend on the geographic mix between the U.S. and OUS markets.

• The commercial launch of additional Motiva implant sizes in the U.S. by year-end 2026 is expected to address approximately 10% of the market that was previously unserved.

Operational Dynamics and Risk Factors

• Q3 performance reflected typical summer seasonality in OUS direct markets, which historically makes it the softest quarter of the year.

• OUS distributor sales reached 60% of international revenue versus the planned 50%, which increased gross profit dollars but moderated the overall gross margin percentage.

• The ongoing conflict in the Middle East has impacted market performance and order levels in that specific region, representing a localized headwind.

• The company is utilizing a payment-in-kind interest provision to save over $5 million in quarterly cash interest, providing flexibility for U.S. expansion.